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SUMMARY
Lymphatic ﬁlariasis (LF), a common parasitic infection in tropical countries, causes lymphoedema of limbs, hydrocele and
acute attacks of dermato-lymphangio-adenitis. Recent advances in diagnosis have helped to recognize that LF infection is
often acquired in childhood. Newly available diagnostic techniques like sensitive antigen and antibody assays, Doppler
ultrasonography and lymphoscintigraphy have helped to understand the subclinical pathology caused by this infection,
which was hitherto generally believed to be irreversible. Recent studies indicate that drugs used in the mass drug
administration (MDA) programme under GPELF are capable of reversing the sub-clinical lymphatic damage in children
and provide beneﬁts other than interruption of transmission. Albendazole and ivermectin used inMDA are eﬀective against
soil-transmitted helminthic infections common in children in LF endemic areas. Thus MDA had other ‘beyond LF’
beneﬁts in treated children including increased appetite, weight gain, greater learning ability and concentration, better
school attendance and prevention of anaemia. MDA should no longer be viewed as a measure for interrupting transmission
alone. Recent ﬁndings of reversibility of early lymphatic pathology in treated children indicate that both MDA and ‘foot-
hygiene’ measures are eﬀective strategies in preventing and managing morbidity. Programme managers should eﬀectively
utilize this information to strengthen their advocacy eﬀorts to achieve high and sustainable coverage in MDA.
Key words: Lymphatic ﬁlariasis, children, subclinical pathology, lymphangiectasia, reversal of lymphatic damage,
prevention, mass drug administration, foot-care.
INTRODUCTION
Lymphatic ﬁlariasis (LF) is a mosquito-borne para-
sitic infection caused by ﬁlarial nematodes invading
the human lymphatic tissue. It is an important public
health problem endemic in 81 tropical countries.
Globally, 1·3 billion people are at risk of this infection
and about 120 million people are estimated to
be aﬀected by this disease (WHO, 2010a). Among
the debilitating vector-borne tropical diseases, LF is
ranked as the second most common cause of
permanent physical disability worldwide (Taylor
et al. 2010). The most common causative agent of
the disease is Wuchereria bancrofti (90%) with, to a
lesser extent,Brugia malayi (<10%) and rarelyBrugia
timori. The various genera of mosquitoes transmit-
ting these parasites in diﬀerent geographical locations
include Culex, Anopheles, Aedes or Mansonia
(Bockarie et al. 2009). LF is still a major cause of
disability and a signiﬁcant impediment to socio-
economic development in large areas of Asia, Africa,
Western Paciﬁc and in certain regions of the Americas
(WHO, 2010b).
The disease manifestations of LF include chronic
lymphoedema and elephantiasis mainly involving the
limbs or sometimes the genital region; also hydrocele
and chyluria, along with acute attacks of recurrent
dermato-lymphangio-adenitis (ADLA) due to bac-
terial infections. These acute attacks are responsible
for the worsening of lymphoedema and progression
to elephantiasis (Pani et al. 1995). These clinical
manifestations aﬀect 44 million people globally.
Studies indicate that once established, the lymphatic
pathology resulting in disease manifestations cannot
be easily reversed by available treatment modalities
(Freedman et al. 1994, 1995; Taylor et al. 2010).
Thus LF is better prevented. The recent advances in
the understanding of pathogenesis of LF, the biology
of the parasite, and development of newer diagnostic
tools and chemotherapeutic agents that are safe
and eﬀective have all contributed to new hope that
this disease can be eradicated globally (Bockarie and
Molyneux, 2009;Taylor et al.2010).ThisGlobalPro-
gramme for Elimination of LF (GPELF) launched
in 2000, is based on a dual approach consisting of
(a) interruption of transmission of LF infection by
treating the entire ‘at risk’ population in endemic
countries by annual single dose administration of
a two-drug combination consisting of albendazole
along with either diethyl carbamazine (DEC) or
ivermectin for a period of 4–6 years and (b) alleviation
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of the disability in those who already have the disease,
by meticulous limb hygiene measures to prevent
secondary bacterial and fungal infections that cause
acute attacks of ADLA (Dreyer et al. 1999; Seim et al.
1999; Ottesen, 2000; Gyapong et al. 2005). GPELF
is a rapidly expanding global health programme,
probably the biggest in the history of public health
(WHO, 2010c). Among the 81 countries considered
endemic for LF, 53 have started implementingMDA
to interrupt transmission. More than 2·8 billion
treatments were delivered to a cumulative targeted
population of 845 million people during 2000 to
2009. Of the 53 countries that have implemented
MDA, 37 (70%) have completed the number of
rounds of MDA thought to be adequate in most
settings to interrupt transmission (55) in some
of their implementation units. According to WHO
estimates (WHO, 2010c), the overall economic
beneﬁt of the programme during 2000–2007 is
around US$24 billion.
Many aspects of LF point to a baﬄing disease. In
the initial stages of infection, when the live adult
worms are present in the lymphatics and usually
associated with microﬁlaraemia, the individual does
not have any outward disease manifestation. There is
a long interval between acquiring the infection and
development of disease manifestations. This ﬁnding
has important implications in the light of the recent
observation that LF infection is acquired in child-
hood in many instances. These children develop
clinical disease mostly in their later adult life (Witt
and Ottesen, 2001; Shenoy, 2006). The knowledge
that children are infected in early life is consequent to
introduction of many newly available diagnostic
techniques like sensitive antigen assays that provide
diagnosis even in low density infections (Weil and
Ramzy, 2007), demonstration of sub-clinical lym-
phatic pathology and detection of presence of live
adult worms in lymphatics by Doppler ultrasono-
graphy (Dreyer et al. 1999; Shenoy et al. 2007b)
and lymph vessel damage by lymphoscintigraphy
(Shenoy et al. 2008).
In the light of these ﬁndings it is quite relevant
to discuss how LF aﬀects the health prospects of
children and the beneﬁts they would accrue by
elimination of this chronic, disabling and depressing
illness from the community. This paper provides an
up-to-date review of various aspects of LF in children
including prevention of this infection.
LYMPHATIC FILARIASIS IN CHILDREN
Over 250 million children are exposed to LF world-
wide. In some endemic communities, up to 10%
of children under the age of 15 years are infected
(Bockarie et al. 2002).More than 100million children
were treated in 2009 by mass drug administration to
eliminate LF (WHO, 2010a). The outward disease
manifestations of LF are seen mostly in adult life,
even though there have been occasional reports from
LF endemic areas of occurrence of lymphoedema and
ADLA attacks in children including hydrocele in
boys of pubertal age (Pani et al. 1991; Ramaiah et al.
1996; Witt and Ottesen, 2001; Weil and Ramzy,
2007). In the past there were several reasons why the
incidence of LF in the paediatric population did not
attract much attention. The foremost among them is
the natural history of this disease, the early stages of
which are remarkably silent and the progression to
later stages of clinical disease is phenomenally slow.
It is well known that the early stage of infection
is characterized by asymptomatic microﬁlaraemia,
which may continue so for varying periods. These
subjects do not have any overt manifestation of the
disease even though they have microﬁlariae (mf) in
their blood, usually detected by blood examination
at night. The routine stained, thick blood-smear
examination was found to be not sensitive enough
to detect all microﬁlaraemics when compared to the
more recently available immunochromatography
(ICT) card test for the detection of ﬁlarial antigen
in bancroftian ﬁlariasis (Weil andRamzy, 2007). This
is specially so when the density of mf is low or when
the infection is in an early stage where the adult
worms have not started producing mf. Even during
this early asymptomatic phase, children are shown to
have dilatation of the lymphatics along with presence
of live adult worms by ultrasonography (Dreyer et al.
1999; Shenoy et al. 2007a) and lymph vessel dilation
by lymphoscintigraphy (Shenoy et al. 2008). This
sub-clinical lymphatic pathology is diﬃcult to
diagnose by external examination. For these reasons,
in the past many of these early infections in children
weremissed.Moreover,many earlier epidemiological
studies did not include children less than 5 years.
Certain epidemiological studies and case reports
in the past and more so in recent times, tests for
ﬁlarial antigenaemia and ultrasound examination of
the lymphatics in children mentioned above have
all indicated that LF may be more importantly
a childhood infection (Witt and Ottesen, 2001).
During the course of research activities in a Brugia
malayi endemic area at the Filariasis Chemotherapy
Unit in TD Medical College Hospital, Alappuzha,
India it was observed that among the asymptomatic,
mf-positive subjects screened*30% were aged 420
years, while 16·3% were <10 years. In a study on
prevention of ADLA attacks in brugian ﬁlariasis, 32%
of the adults who had lymphoedema of several years
duration recalled during their interview, that their
disease ﬁrst manifested before they were 15 years of
age (Suma et al. 2002).
Factors inﬂuencing LF infection in children
Many past studies have reported clustering of young
individuals with mf in a given household. This has
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been attributed to several mechanisms such as
environmental factors facilitating exposure to infec-
tive mosquito bites (Vanamail et al. 1989, 1992)
intra-uterine sensitisation due to maternal infection,
higher prevalence of mf in children born to microﬁ-
laraemic mothers (Lammie et al. 1991) and parental
infection (maternal, paternal or both) predisposing to
higher prevalence of mf in the oﬀspring (Das et al.
1997). Exposure to infection within the household
appeared to be the most important cause for acquir-
ing LF infection in childhood, more than prenatal
sensitisation or genetic factors (Das et al. 1997).
Clinical features of LF disease in childhood
Onewell known clinical presentation of LF disease in
the paediatric group is non-speciﬁc lymph node
enlargement or soft tissue swelling in the inguinal
region, axilla or neck. Biopsy and histopathological
examination of such swellings had conﬁrmed pres-
ence of dead adult ﬁlarial worms or their remnants
(Jungmann et al. 1991). Several studies from endemic
areas for LF have recorded the presence of lymphoe-
dema of limbs in children, the incidence being higher
in older children (Fig. 1). Higher grades of oedema
are not common since this depends upon the duration
of the illness. Hydrocele of the scrotal sac is also
described in boys of pubertal age or older. Acute
attacks of ADLA were noted in children both with
andwithout lymphoedema (Pani et al. 1991; Ramaiah
et al. 1996; Fox et al. 2005). Episodes of ADLA
are characterized by acute onset pain, fever, redness
and tenderness of aﬀected limb along with other
constitutional symptoms like vomiting. The draining
lymph nodes are usually painful and tender. The
chronic manifestations are seen less often in children
<10 years. In a recent study in a Brugia malayi
endemic region, out of 7934 children screened for
ﬁlarial infection and disease four girls between 10–15
years old had grade II lymphoedema (Shenoy et al.
2007a). Occasionally they present with ﬁlarial lym-
phangitis caused by death of the adult worms in the
lymphatics, either spontaneous or after treatment
with the antiﬁlarial drug DEC. In such situations
dilated, inﬂamed and tender lymphatic channels
stand out as cords (“string sign”) seen and palpated
either by the side of the chest or inguinal region
(Shenoy et al. 1998). Rarely chyluria and tropical
pulmonary eosinophilia are also reported in children
(Witt and Ottesen, 2001).
Microﬁlaraemia in children
Studies in diﬀerent endemic populations on mf
prevalence have shown a constant relationship
between childhood and adult infections. The child-
hood mf prevalence rates were *30% of adult
prevalence for <10 year olds and *69% for 10–19
years olds (Witt and Ottesen, 2001). The mf counts
tended to be lower in young children and were higher
in older children. Oﬀspring of microﬁlaraemic
mothers had a higher risk of microﬁlaraemia when
compared to those born of uninfected mothers
(Alexander et al. 1998). In a study of Brugia malayi
ﬁlariasis, 32 children were detected to have microﬁ-
laraemia ranging from 28 to 1812/ml, three of them
being just three years old (Shenoy et al. 2007a).
Immuno-diagnosis of LF infection in childhood
For bancroftian ﬁlariasis there are two sensitive tests
presently available for detection of circulating ﬁlarial
antigen, which can be carried out even during
daytime in contrast to detection of mf by examination
of blood at night. These are ICT card test and Og4C3
antibody based test in ELISA format (Weil
and Ramzy, 2007). A positive test result indicates
presence of live adult worms and thus active
infection. The ICT card test is easier to perform
than the ELISA test. Longitudinal studies con-
ducted in children from endemic areas have demon-
strated ﬁlarial antigenaemia in 6% of the two-year
olds and the prevalence increased to 30% in four-year
olds (Lammie et al. 1998). Test for the adult worm
antigen is deﬁnitely a more sensitive method than
blood mf counts to detect LF prevalence in children.
If only the mf detection method by night blood
examination is used for diagnosis, at least one-third of
all infections would be missed (Witt and Ottesen,
2001). The ﬁlarial antigen prevalence (AGP) rates are
always higher than the mf prevalence (MFP) in many
ﬁeld studies. One such study reported that AGP seen
Fig. 1. Advanced lymphoedema in the left leg of a
14 year-old girl from an area endemic for lymphatic
ﬁlariasis.
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on ICT test was higher than MFP varying between
11·3 to 12% (Sunish et al. 2002). In another study,
while 62% children had microﬁlaraemia, 81% had
antigenaemia on Og4C3 testing (Fox et al. 2005).
Such antigen detection tests as described above are
not available so far for a speciﬁc diagnosis of Brugia
malayi infection. But a ﬁlaria-speciﬁc IgG4 antibody
test using a recombinant antigen (BmR1) has been
developed, which has 95–97% sensitivity, 99%
speciﬁcity, 97% positive predictive value and 99%
negative predictive value (Rahmah et al. 2001, 2003).
This test is available in an ELISA format, as a
dipstick test termed ‘Brugia Rapid’ (BR) and also in
cassette form. The BR test was used in a study of LF
infection in children in aBrugia-endemic area, where
7934 children were screened in villages for ﬁlarial
infection and disease. In this population, it was found
on screening that, while the prevalence of microﬁ-
laraemia by blood-smear examination was only
0·38%, the BR test was positive in 10·97%. Similar
to what is seen by ICT card testing in bancroftian
ﬁlariasis, the BR test thus identiﬁed nearly 27 times
more ‘infected’ individuals inBrugia malayi infection
than the conventional mf detection by blood smear
examination (Shenoy et al. 2007a, 2009). From
the above group, 100 children were enrolled for
the chemotherapy studies, out of which 77 tested
positive for ﬁlaria-speciﬁc IgG4 antibody. This IgG4
positive group had more individuals who had other
unmistakable evidence of ﬁlarial infection or sub-
clinical lymphatic pathology. Thus it was seen that
94% of the microﬁlaraemics, 86% of the children
with live adult worm ‘nests’ detected on Doppler
ultrasonography and 78% of the children who had
abnormal lymphatics on lymphoscintigraphy (LSG)
were IgG4 positive. Based on these observations
it was concluded that a positive BR test is a reliable
marker of B. malayi infection (Shenoy et al. 2009).
Doppler and ultrasonography in LF infection
in children
One of the important recent tools in the diagnosis of
LF infection is ultrasonography (USG) and Doppler
sonography (DSG) (Shenoy et al. 2007a). Live adult
worm nests, hydrocele, chylocele and lymph vessel
dilatation (lymphangiectasia) can be detected by
this procedure. As with adult males, older children
with asymptomatic bancroftian microﬁlaraemia
were shown to harbour live adult worms in the
scrotal lymphatics. Ultrasound examination using a
7·5MHz probe in eight boys aged 14–16 years
revealed the existence of adult ﬁlarial worms indi-
cated by the ‘ﬁlaria dance sign’ (FDS) in the ‘nests’
along with diﬀuse dilatation of the lymphatic vessels.
FDS was also present in crural lymphatics and
axillary lymph node in two girls aged 9 and 7 years
respectively. FDS was detected even in one
amicroﬁlaraemic child (Dreyer et al. 1999). USG is
not as sensitive as mf detection on ‘night’ blood
examination or tests for antigenaemia. Thus one
study of W. bancrofti (WB) LF in 5–13 year old
children found that while microﬁlaraemia was pre-
sent in 62% and antigenaemia in 81%, FDS was seen
only in 15% (Fox et al. 2005).
InBrugia malayi infection where there is no genital
involvement, one study using ultrasonography with a
7·5MHz probe failed to locate any adult worm nests
in the scrotal lymphatics in adults. It was concluded
that this failure to demonstrate B. malayi (BM)
parasites was due to either technological inadequacies
(resolution of the probe, lack of Doppler techniques)
or possibly due to intrinsic biological characteristics
of the worm such as their smaller size, ability to locate
to deeper tissues or inability to populate classical
bancroftian locations such as the scrotal lymphatics
(Shenoy et al. 2000). Thus in the recent study of BM
infection in children, Colour Power Doppler (CPD)
and Pulse Wave Doppler (PWD) examination were
employed to locate adult worm nests, if any were
present. This additional facility is essential to locate
with conﬁdence the small adult worm nests in BM
infection and diﬀerentiate them from the echoes from
blood vessels (Mand et al. 2006). By this method
18 nests with FDS were identiﬁed in 14 children
comprising 11 boys and 3 girls. Four subjects had two
‘nests’ each. The youngest two children who showed
FDS were only 3 years old. FDS was seen in the
axilla in 12 children, in the thigh in two and in the
epitrochlear and popliteal area in one child each
(Fig. 2A and 2B). The worm nests were distinctly
smaller and the wriggling movements were less rapid
and less conspicuous than those of bancroftian
ﬁlariasis. Lymph vessel dilations were observed on
DSG in 38 out of the 100 enrolled children (Shenoy
et al. 2007a).
Lymphoscintigraphy in LF infection in children
Lymphoscintigraphy has been carried out earlier in
subjects with established lymphoedema of the limbs
to delineate the underlying pathology of the lymph
vessels and lymph nodes such as delayed or absent
transport of the radiotracer, tortuous and bizarre
deep lymphatics, dermal diﬀusion, retrograde tracer
ﬂow and faint or absent regional nodal visualization
(Witte et al. 1993). More recently, lymphoscinti-
graphic studies have documented abnormal lym-
phatics even in asymptomatic individuals who had
only circulating microﬁlaraemia due to W. bancrofti
infection suggesting that lymphatic damage preceded
onset of clinical disease (Freedman et al. 1994).
In a B. malayi-endemic area LSG was carried out
in 100 children, 3–15 year-olds, who had either
asymptomatic microﬁlaraemia, history or evidence of
ﬁlarial disease or were positive for ﬁlariasis-speciﬁc
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IgG4 antibody. This was done by intradermally
injecting 0·5 ml of a solution containing 2 μCi
of Tc99m-tagged sulphur colloid into the ﬁrst web
spaces of both feet and hands and the lymphatics were
imaged using gamma camera (Shenoy et al. 2007b).
Dilated lymphatic channels were seen in 80 of the 100
children. This included 81% of the microﬁlaraemics
(Fig. 3A and 3B), 79% children with ﬁlarial disease
and 79% of those who were only IgG4 positive. Five
children who had lymph vessel dilation were only
three years old. Dilated lymph vessels (LV), with
tortuosity in some subjects, were commonly seen in
the lower limbs. Upper limb involvement was less
common. Both in the upper and lower limbs the
entire length of the aﬀected lymphatics appeared
dilated. Inguinal, axillary and less commonly popli-
teal or epitrochlear lymph nodes were visualized on
lymphoscintigraphy in all the 100 children examined.
This study demonstrated that LF infection in
children is associated with subclinical pathology
even in the pre symptomatic phase of the infection
when they had only microﬁlaraemia or were only
IgG4 positive (Shenoy et al. 2008).
Histopathology of LF infection in children
Anotuncommonclinicalmanifestationofbancroftian
ﬁlariasis in children in endemic areas is presentation
with enlarged lymph nodes or soft tissue swellings
in the axilla, groin or neck. Biopsy and histopatho-
logical studies of these lymph nodes and tissues
demonstrated the presence of adult ﬁlarial parasites
and mf associated with marked dilation of lymph
vessels in these children who did not have any other
evidence of ﬁlarial disease (Figueredo-Silva et al.
1994; Dreyer et al. 2001). The fact that lymphan-
giectasia is not restricted to the exact segment where
the adult worms are located indicates that it may be
the result of the action of soluble parasite-speciﬁc
factors or excretory products on responsive lymphatic
endothelial cells. Live parasites were not associ-
ated with any inﬂammatory reaction in the lymph
vessels, while dead worms induced granulomatous
inﬂammatory reaction with variable numbers of
eosinophils, lymphocytes, plasma cells and large
macrophages. There may be large numbers of
eosinophils, especially in cases treated with DEC
(Figueredo-Silva et al. 2002).
Another important aspect of the pathology of LF
has been the ﬁnding that the bacterial endosymbionts
Wolbachia, present in the ﬁlarial parasites, may
be responsible for the inﬂammatory process associ-
ated with the progression of this disease. Exposure
to Wolbachia lipoproteins could be responsible
for promoting lymphangiogenesis, lymphatic endo-
thelial proliferation and dilation of lymph vessels,
which are known to result in chronic manifestations
of LF disease (Taylor et al. 2010). Studies are needed
on this aspect of LF in children.
Social and psychological impact of LF in the young
LF disease poses several important problems
in childhood and adolescence. The social and
A B
Fig. 2. (A). Ultrasound examination (B mode) of the right axilla of a 9 year-old male with asymptomatic microﬁlaremia
showing the site of a dilated lymph vessel (arrow) with the ‘ﬁlaria dance sign’ (FDS), indicating presence of adult
parasite ‘nest’. (B). Colour Power Doppler (CPD) examination of the site of FDS above. Arrow points to the area of
FDS, which shows irregular mosaic signals on CPD that are diﬀerent from the characteristic signals produced from
blood vessels.
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psychological impact of this malady in this age group
had been addressed in some studies in the aﬀected
communities. The clinical manifestations of LF in
the younger age group were associated with social
stigma and psychological problems that interfered
with their education and self-conﬁdence. In a
study conducted in two villages in South India, 28
subjects aged <20 years had clinical manifestations
that included lymphoedema and ADLA attacks.
Hydrocele was present in boys aged 10–15 years.
Their social problems included feeling of shame,
embarrassment and ridicule especially due to hydro-
cele. The presence of hydrocele and lymphoedema
even interfered with their conventional school dress.
Frequent absence from school due to the acute attacks
and sometimes discontinuation of studies in this
population would have socio-economic implications
for their future (Ramaiah and Vijay Kumar, 2000).
This chronic disease may thus interfere with the
quality of life of these children as they develop.
Diagnosis of LF infection and disease in children
Children living in LF-endemic communities have a
higher risk of developing the infection, which is
ﬁrst acquired by many in their early childhood itself.
The dilatation of the lymphatics, which is the early
and basic sub-clinical pathology induced by the adult
worms, once established is reported to be irreversible
even with treatment (Freedman et al. 1995). In
the aﬀected limbs this persistent lymphatic damage
predisposes to later development of lymph stasis,
secondary bacterial infections precipitating ADLA
attacks, consequent development of lymphoedema
and its progression (Shenoy et al. 1999). Therefore
detection of LF infection in the early asymptomatic
stage itself and prompt treatment are important
in preventing future chronic disability. The investi-
gations that are useful for diagnosis in the early stages
are examination of thick blood-smears obtained
at night for presence of mf; Nuclepore membrane
ﬁltration to quantify the parasitaemia, ICT card test
or Og4C3 test for ﬁlarial antigenaemia in WB
infection and ﬁlariasis-speciﬁc IgG4 antibody test
in BM infection. USG andDSGmay be employed in
doubtful situations to detect any FDS, though this is
not as speciﬁc as the other two methods. LSG being
a costly investigation is rarely employed for routine
diagnosis of LF infection. There is scope for future
development of diagnostics in LF infection in
children such as reﬁnement in the use of PCR tech-
nique and detection of ﬁlariasis-speciﬁc antigen/
antibodies.
Once the subject presents with swelling of the
limbs or with an ADLA attack, a clinical diagnosis of
LF is suspected under certain circumstances such
as the subject residing in a region endemic for LF,
familial clustering of such cases, swelling more often
unilateral involving the lower limbs or rarely upper
limbs of long duration except during initial stages and
asymmetry of the swelling when bilateral. The
oedema is pitting in early stages, though non-pitting
due to thickening of skin in the later stages. This stage
A B
Fig. 3. (A). Lymphoscintigraph of a 9 year-old boy with asymptomatic microﬁlaraemia showing lymph vessel dilation
in both legs (left panel). (B). Note absence of lymph vessel dilation in the legs on 30 months follow up, after
administration of ﬁve doses of DEC and albendazole once every six months.
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is uncommon in children since the thickening of skin
depends on longer duration of disease. Presentation
with lymphoedema or hydrocele are seen mostly in
children >10 years of age.
In special situations, investigations like CT, MRI
and MR angiography are sometimes employed in
children to diﬀerentiate ﬁlarial swelling from other
causes of lymphoedema like malformations of lymph
vessels seen in association with certain congenital
diseases (Stanton et al. 2000).
Management of LF infection and disease in children
Treatment of LF infection. DEC is the drug of
choice when there is active infection from W. ban-
crofti, B. malayi or B. timori. Though it is very
eﬀective as a microﬁlaricidal agent, DEC kills only
around 50% of adult worms. Even though the
standard dose of DEC recommended in LF over
the years was 6mg/kg daily for 12 days, recent studies
have shown that a single dose of 6 mg/kg is as eﬀective
as the 12-day course both against the mf and adult
worms (Gyapong et al. 2005). In early stages of
lymphoedema, DEC may be helpful if there is active
ﬁlarial infection and its use might prevent further
lymphatic damage through itsmacroﬁlaricidal action.
The other antiﬁlarial drugs, ivermectin and albenda-
zole, even though important in the sustained
reduction of blood mf levels and arresting LF trans-
mission, have no role in the management of lym-
phoedema or acute attacks.
Treatment of ADLA. These attacks can easily be
treated and further episodes prevented. Bed rest,
elevation of the aﬀected limb and symptomatic
treatment with simple drugs like paracetamol are
suﬃcient in mild cases. Any local precipitating ‘entry
lesions’ like injury and bacterial or fungal infection
should be treated with local antibiotic or antifungal
ointments or with systemic antibiotics where
needed. Proper and regular practice of ‘local hygiene’
measures of the aﬀected limbs are eﬀective in prevent-
ing ADLA attacks (Shenoy et al. 1998). This is aimed
at prevention of fungal and bacterial infections and
has become the mainstay for disability alleviation in
GPELF (Ottesen, 2000).
Treatment of lymphoedema. In early lymphoedema,
occasionally seen in older children, applying elasto-
crepe bandage to the aﬀected limb while ambulant
and keeping the limb elevated at night are eﬀective to
obtain relief.
Anti-Wolbachia therapy in LF. Studies in adults
with LF infection have documented the encouraging
results of treatment with doxycycline at 200mg daily
given for varying periods from 3 to 8 weeks. This has
resulted in long-term sterility and eventual death of
the adult worms (Taylor et al. 2010). There are
presently no reports of such a protracted course of
doxycycline treatment in children with LF. Due to
the adverse eﬀects that doxycycline is known to cause,
this drug is generally not used in pregnant women
and children (Taylor et al. 2010). It may be recalled
here that in a recent study on BM infection in
children the presently available anti-ﬁlarial drugs
are generally well tolerated and eﬀective in clearing
microﬁlaraemia and the FDS indicating presence of
live adult worms and also in reversing the early sub-
clinical lymphatic pathology (Shenoy et al. 2009).
Prevention of LF infection and disease in children
Prevention of ﬁlarial infection in children can be
achieved either through arresting the parasite trans-
mission by reducing the mf load in the community
employing mass drug administration (MDA), by
thorough vector control or by preventing man-vector
contact. Of these, MDA initiated by GPELF is
now the most eﬀective method since 2000. Presently
53 out of the initially identiﬁed 81 LF-endemic
countries are under MDA (WHO, 2010c).
In countries endemic for bancroftian infection, 4–6
annual rounds of MDA have been found to be
eﬀective in lowering the mf levels in the community,
in reducing the ﬁlarial antigen levels in the popu-
lation including children and thus preventing
parasite transmission in the treated communities
(Ramaiah et al. 2002, 2007). In children from a WB-
endemic area treated with DEC and albendazole,
FDS indicating adult worm nests disappeared after
treatment (Fox et al. 2005). In assessing the impact
ofGPELF after 8 years of its institution, it is reported
that this has prevented LF disease in 6·6 million
newborns who would otherwise have acquired LF,
thus averting in their lifetimes nearly 1·4 million
cases of hydrocele, 800,000 cases of lymphoedema
and 4·4 million cases of subclinical disease (Ottesen
et al. 2008).
In a recently published study in children with
Brugia malayi infection in India, it was demonstrated
for the ﬁrst time that anti-ﬁlarial drugs in doses
employed inMDA by the GPELF, reversed the sub-
clinical lymphatic pathology. In this study, tests
for antiﬁlarial IgG4, Doppler ultrasonography and
lymphoscintigraphy were employed to identify the
sub-clinical pathology in 100 children. They were
either asymptomatic microﬁlaraemic, amicroﬁlarae-
mic but had past or present ﬁlarial disease or were
asymptomatic amicroﬁlaraemic but positive only for
IgG4. Theywere treated every sixmonths with single
combined doses of DEC (6mg/kg) and albendazole
(400mg) and followed up for three years. At the end
of three years all children were amicroﬁlaraemic,
FDS was abolished in the 14 children who were
initially positive and the lymphoedema (grade II) had
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disappeared in all the four girls who had it initially.
Lymphoscintigraphy at the last follow-up revealed
that the lymph node and vessel damage observed
during enrollment had reversed in 89·6% children.
They included 96% of the mf positives, 85% of those
with ﬁlarial disease and 87·5% of those who were only
positive for IgG4 (Shenoy et al. 2009). These results
suggest that MDA is eﬀective in reversing the sub-
clinical pathology induced by the adult worms in
children, if they are treated early in LF infection.
This is in contrast to the ﬁndings reported in adults
that the sub-clinical pathology once established is
irreversible even with treatment (Freedman et al.
1995).
In the context of GPELF, the present guidelines
for interruption of LF transmission require that after
achieving a microﬁlaraemia prevalence status of <1%,
a sample of 3000 children in the age group of 6–10
years should be tested for ﬁlarial antigenaemia
with the ICT card test. If one or more children are
positive,MDA has to be continued and also that such
children are investigated and treated (WHO, 2000).
This indicates the importance of parasitaemia in
children in the transmission of LF.
In the present scenario of integrated vector
management, the use of mosquito repellant-impreg-
nated bed nets will be helpful in preventing LF
infection in children in communities where there is
co-endemicity of malaria, ﬁlariasis and other vector-
borne parasitic infections.
DISCUSSION
It is being increasingly appreciated that, in endemic
countries, ﬁlarial parasites infect children early in
life. Though asymptomatic at this stage, recently
available diagnostic techniques have made it possible
to recognize LF infection and sub-clinical lymphatic
damage in children. Apart from microﬁlaraemia,
circulating ﬁlarial antigen in WB infection, ﬁlariasis-
speciﬁc IgG4 antibody in BM infection, ‘nests’ of live
adult parasites in the lymphatics and the subclinical
changes in the lymph vessels can all now be detected.
The sub-clinical pathology caused by the adult
worms in infected children is extensive in the aﬀected
lymph vessels, though these subjects do not have
disease manifestations until later in their adult life
(Figueredo-Silva et al. 2002; Shenoy et al. 2008).
The gravity of this public health issue in LF-endemic
countries can be understood when it is known that
LF infection occurs in 10% of the ‘at-risk’ popu-
lation; 66·7% of such infections have sub-clinical
damage, 20·8% result in hydrocele and 12·5% result in
lymphoedema (Ottesen et al. 2008).
TheMDAunderGPELF being carried out among
the ‘at-risk’ population in endemic countries for the
last nine years has prevented disease in many children
born afterMDA commenced (Ottesen et al. 2008). In
this programme children aged 2 years and above are
included. The drug albendazole, with either DEC or
ivermectin, used in mass drug treatment is mainly
aimed at preventing parasite transmission and ulti-
mately eliminating LF infection in treated commu-
nities. The intention is thus primary prevention of
the disease. In the last eight years, MDA is estimated
to have prevented LF disease in 6·6 million future
newborns and averted in their lifetimes nearly 1·4
million cases of hydrocele, 800,000 cases of lym-
phoedema and 4·4 million cases of subclinical disease
which they would otherwise are expected to develop
(Ottesen et al. 2008).
There have been many earlier reports indicating
the beneﬁcial eﬀects of drugs used inMDA especially
DEC, such as improvement or reduction in the
incidence of lymphoedema, hydrocele and ADLA
in treated communities (March et al. 1960;
Meyrowitsch and Simonsen, 1998; Bockarie et al.
2002; Meyrowitsch et al. 2004). Hitherto the
assumption has been that the underlying lymphan-
giectasia could not be reversed even after treatment.
Now it has been shown that, at least in B. malayi
infection in children, the sub-clinical pathology
can be reversed by the drugs DEC and albendazole
in doses used in MDA (Shenoy et al. 2007a). This
indicates that MDA is also capable of secondary
prevention of LF. This ﬁnding has tremendous
impact in the present LF elimination campaign.
The ‘foot care’ or ‘limb hygiene’ programme
recommended under disability management of
GPELF is very eﬀective in preventing the occurrence
of acute ADLA attacks in LF. These episodes are
responsible for worsening the lymphatic damage and
future development of swelling in the limbs (Shenoy
et al. 1999). In children having asymptomatic LF
infection, the underlying sub-clinical lymphatic
damage predisposes them to acute attacks following
minor injuries or bacterial skin infections. They are
thus prone to develop lymphoedema which, when
established, is diﬃcult to reverse. So to prevent this
disability, regular ‘foot-care’ must be instituted in
‘at-risk’ children in endemic communities from an
early age. Innovative approaches, such as introduc-
tion of this foot-care programme in the school
curriculum in endemic areas, would be a progressive
step in this direction (Shenoy, 2006).
Apart from elimination of LF infection, mass
treatment of children in endemic countries with
albendazole and ivermectin has been shown to have
other ‘beyond-LF’ beneﬁts. Both these drugs are also
eﬀective against intestinal, soil-transmitted hel-
minthiases (STH), namely hookworm, roundworm
and whipworm infection, which are very common in
children. In addition, ivermectin is eﬃcacious against
Strongyloides stercoralis. Recent studies indicate that
combining ivermectin and albendazole result in high
cure rates in Trichuris trichura infection also (Knopp
et al. 2010). STH infections are prevalent throughout
the pan-tropical belt where LF is endemic (de Silva
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et al. 2003). Mass treatment with these drugs has
beneﬁcial eﬀects in treated children including in-
creased appetite and weight gain, greater learning
ability and concentration, better school attendance
and prevention of anaemia (Stephenson et al. 1993;
Adams et al. 1994).
The above ﬁndings support the need for strength-
ening eﬀorts to ensure high treatment coverage
among eligible children ‘at-risk’ since the beneﬁts
extend well beyond clearance of LF infections.
Programme managers and pediatricians in endemic
countries recognizing the ‘invisible disability’ im-
posed by ﬁlarial infection should institute simple
measures of hygiene to alleviate morbidity in these
children. MDA should no longer be viewed as a
measure for interrupting transmission alone. Recent
ﬁndings of reversibility of early lymphatic pathology
in treated children provide ample proof that both
the MDA strategy and ‘foot-hygiene’ measures can
be viewed as an eﬀective measure in preventing and
managing morbidity. Programme managers should
eﬀectively utilize this information to strengthen their
advocacy eﬀorts to achieve high and sustainable
coverage in MDA (Shenoy et al. 2009).
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